Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabendu Pore

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Neoplasia (New York, N.Y.)|July 9, 2015
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic TumorsNabendu Pore, Sanjoo Jalla, Zheng Liu, et al.
Cancer Research|May 8, 2007
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavirZibin Jiang, Nabendu Pore, George J Cerniglia, et al.
Cancer Research|September 20, 2006
Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapyNabendu Pore, Anjali K Gupta, George J Cerniglia, et al.
Molecular Biology of the Cell|September 3, 2004
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanismNabendu Pore, Shuang Liu, Hui-Kuo Shu, et al.
Nuclear Medicine and Biology|July 20, 2023
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, Nancy Guo, et al.
Plos One|August 7, 2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyGeorge J Cerniglia, Nabendu Pore, Jeff H Tsai, et al.
Leukemia & Lymphoma|October 15, 2024
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaMeletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Neoplasia (New York, N.Y.)|July 9, 2015
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic TumorsNabendu Pore, Sanjoo Jalla, Zheng Liu, et al.
Cancer Research|May 8, 2007
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavirZibin Jiang, Nabendu Pore, George J Cerniglia, et al.
Cancer Research|September 20, 2006
Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapyNabendu Pore, Anjali K Gupta, George J Cerniglia, et al.
Molecular Biology of the Cell|September 3, 2004
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanismNabendu Pore, Shuang Liu, Hui-Kuo Shu, et al.
Nuclear Medicine and Biology|July 20, 2023
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, Nancy Guo, et al.
Plos One|August 7, 2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyGeorge J Cerniglia, Nabendu Pore, Jeff H Tsai, et al.
Leukemia & Lymphoma|October 15, 2024
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaMeletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 2